Toremifene For Bone Fractures

Last week, GTx Inc. announced the FDA plans to make a ruling on the company's bone drug toremifene by Oct. 30. The drug is intended to prevent bone fractures in men who are undergoing androgen deprivation therapy (ADT) for prostate cancer. GTx has asked the FDA to approve marketing for 80 mg doses of toremifene. Approximately 100,000 men undergo ADT each year and this treatment has a tendency to weaken bones, leading to five to eight percent of men treated with ADT to suffer a bone fracture.

Have a good Thursday.
Blessings,
Rick

Freezing Tumors?

Freezing Tumors Shown to Reduce Presence of Side Effects
Researchers in Orlando say freezing away prostate tumors, a treatment called focal cryoablation, is as effective as surgery and avoids life-changing side effects. The treatment destroys cancerous tissue with extremely cold gas fired through needle probes without damaging surrounding tissue.
"There were no local recurrences in the areas we treated, and with the ability to re-treat the 7 percent of patients who developed a focus of cancer at a different site in the gland, cryoablation was 100 percent effective in local control of the patient's disease," said Dr. Gary Onik, director of the Center for Safer Prostate Cancer Therapy.
Additionally, sexual function was retained by 85 percent of men in the study and all those who did not have previous prostate surgery remained continent.

Have a good Wednesday.
Blessings,
Rick